Company Quick10K Filing
Opiant Pharmaceuticals
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 5 $68
10-Q 2019-11-12 Quarter: 2019-09-30
10-Q 2019-08-08 Quarter: 2019-06-30
10-Q 2019-05-09 Quarter: 2019-03-31
10-K 2019-03-21 Annual: 2018-12-31
10-Q 2018-11-07 Quarter: 2018-09-30
10-Q 2018-08-09 Quarter: 2018-06-29
10-Q 2018-05-08 Quarter: 2018-03-31
10-Q 2017-12-04 Quarter: 2017-10-31
10-K 2017-10-13 Annual: 2017-07-31
10-Q 2017-06-14 Quarter: 2017-04-30
10-Q 2017-03-15 Quarter: 2017-01-31
10-Q 2016-12-15 Quarter: 2016-10-31
10-K 2016-10-28 Annual: 2016-07-31
10-Q 2016-06-08 Quarter: 2016-04-30
10-Q 2016-03-15 Quarter: 2016-01-31
10-Q 2015-12-14 Quarter: 2015-10-31
10-K 2015-10-26 Annual: 2015-07-31
10-Q 2015-06-12 Quarter: 2015-04-30
10-Q 2015-03-17 Quarter: 2015-01-31
10-Q 2014-12-09 Quarter: 2014-10-31
10-K 2014-10-27 Annual: 2014-07-31
10-Q 2014-06-10 Quarter: 2014-04-30
10-Q 2014-03-17 Quarter: 2014-01-31
10-Q 2013-12-16 Quarter: 2013-10-31
10-K 2013-10-29 Annual: 2013-07-31
10-Q 2013-06-14 Quarter: 2013-04-30
10-Q 2013-03-18 Quarter: 2013-01-31
10-Q 2012-12-20 Quarter: 2012-10-31
10-K 2012-10-29 Annual: 2012-07-31
10-Q 2012-06-14 Quarter: 2012-04-30
10-Q 2012-03-16 Quarter: 2012-01-31
10-Q 2011-12-15 Quarter: 2011-10-31
10-K 2011-10-31 Annual: 2011-07-31
10-Q 2011-06-13 Quarter: 2011-04-30
10-Q 2011-03-17 Quarter: 2011-01-31
10-Q 2010-12-14 Quarter: 2010-10-31
10-K 2010-11-15 Annual: 2010-07-31
10-Q 2010-06-11 Quarter: 2010-04-30
10-Q 2010-03-16 Quarter: 2010-01-31
8-K 2020-02-18 Other Events
8-K 2020-01-17 Other Events
8-K 2020-01-09 Other Events
8-K 2020-01-08 Officers
8-K 2019-11-14 Enter Agreement, Exhibits
8-K 2019-11-12 Earnings, Exhibits
8-K 2019-08-08 Earnings, Exhibits
8-K 2019-07-11 Amend Bylaw, Exhibits
8-K 2019-06-12 Shareholder Vote
8-K 2019-05-09 Earnings, Exhibits
8-K 2019-04-09 Other Events
8-K 2019-03-21 Earnings, Exhibits
8-K 2019-02-21 Other Events, Exhibits
8-K 2019-01-15 Officers
8-K 2019-01-04 Officers
8-K 2018-12-28 Enter Agreement, Exhibits
8-K 2018-11-07 Earnings, Exhibits
8-K 2018-11-01 Officers
8-K 2018-10-29 Officers, Other Events, Exhibits
8-K 2018-09-27 Enter Agreement, Other Events, Exhibits
8-K 2018-09-25 Other Events, Exhibits
8-K 2018-09-20 Enter Agreement, Other Events, Exhibits
8-K 2018-09-10 Enter Agreement, Other Events, Exhibits
8-K 2018-08-09 Earnings, Exhibits
8-K 2018-06-13 Officers
8-K 2018-06-12 Officers, Exhibits
8-K 2018-06-11 Shareholder Vote, Other Events, Exhibits
8-K 2018-05-10 Earnings, Exhibits
8-K 2018-04-18 Other Events, Exhibits
8-K 2018-02-27 Other Events, Exhibits
8-K 2018-02-12 Other Events, Exhibits
8-K 2018-02-08 Earnings, Exhibits
8-K 2018-01-16 Officers, Exhibits
8-K 2018-01-02 Other Events, Exhibits

Opiant Pharmaceuticals Financials

OPNT Metrics, Comps, Filings

Annual | Quarterly

Business

On December 8, 2017, the Board of Directors of Opiant Pharmaceuticals, Inc. ("we", "our" or the "Company"), acting pursuant to Section 5.1 of the Company's Bylaws, approved a resolution changing the Company's fiscal year end from July 31 to December 31. We made this change to align our fiscal year end with other companies within our industry. Certain information contained in this section will align with the Company's financial statement reporting for the year ended December 31, 2018, the five months ended December 31, 2017 and the fiscal year ended July 31, 2017.

We are a specialty pharmaceutical company developing medicines for addictions and drug overdose. We were incorporated in the State of Nevada in June 2005 as Madrona Ventures, Inc. and, in September 2009, we changed our name to Lightlake Therapeutics Inc. In January 2016, we again changed our name to Opiant Pharmaceuticals, Inc.

On October 2, 2017, we changed our state of incorporation from the State of Nevada to the State of Delaware pursuant to an Agreement and Plan of Merger, dated October 2, 2017 whereby we merged with and into our recently formed, wholly-owned Delaware subsidiary, Opiant Pharmaceuticals, Inc. Pursuant to the Agreement and Plan of Merger, (i) we merged with and into our Delaware subsidiary, (ii) our separate corporate existence in Nevada ceased to exist, (iii) our Delaware subsidiary became the surviving corporation, (iv) each share of our common stock, $0.001 par value per share (the "Common Stock"), outstanding immediately prior to the effective time was converted into one fully-paid and non-assessable share of common stock of Opiant Pharmaceuticals, Inc., a Delaware corporation, $0.001 par value per share, and (v) the certificate of incorporation and bylaws of our Delaware subsidiary were adopted as our certificate of incorporation and bylaws at the effective time of the merger. The merger and the Agreement and Plan of Merger were approved by our Board of Directors (the "Board") and stockholders representing a majority of outstanding Common Stock.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
International Tower Hill Mines (THM) 107 -22.5 -7% 64 0 0 0 -4 -4 99
EMX Royalty (EMX) 88 0% 115 6 0 0 0 0 2
Vista Gold (VGZ) 77 -7.1 -63% 18 2 0 -3 -12 -11 76
Entree Resources (EGI) 72 0% 7 47 0 0 0 0 66
Almaden Minerals (AAU) 72 0% 74 3 0 0 0 0 69
Opiant Pharmaceuticals (OPNT) 68 32% -4.1 -37% 29 9 21 7 -11 -11 44
Caledonia Mining (CMCL) 56 0% 126 47 0 0 0 0 56
Platinum Group Metals (PLG) 52 0% 42 61 0 0 0 0 52
General Moly (GMO) 51 -5.6 -3% 328 57 0 0 -9 -8 45
China Natural Resources (CHNR) 45 0% 8 30 0 0 0 0 45
Pershing Gold (PGLC) 37 -2.4 -44% 32 4 0 -2 -14 -14 35
Avino Silver & Gold Mines (ASM) 37 0% 109 33 0 0 0 0 34
Golden Minerals (AUMN) 30 0% -8.3 -39% 11 7 6 0 -4 -3 28
Paramount Gold Nevada (PZG) 22 0% -3.6 -12% 49 2 0 0 -6 -6 22
Solitario Zinc (XPL) 22 -23.7 90,800,000% 0 0 -1 -1 21
Comstock Mining (LODE) 16 0% -6.5 -25% 34 26 0 0 -8 -4 25
Westwater Resources (WWR) 10 -0.3 -63% 28 12 0 0 -18 -18 5
Wheaton Precious Metals (WPM)
B2Gold Corp (BTG)
Great Panther Silver (GPL)

Balance Sheet ($MM)2013-07-312014-07-312015-07-312016-01-312016-07-312017-07-312018-12-31
Cash10011725
Accounts Receivable044
Inventory
PP&E000
Assets100121129
Accounts Payable
Long-Term Debt0
Liabilities23967613
Stockholders' Equity-1-3-8-5-5417
Income Statement ($MM)2013-07-312014-07-312015-07-312016-01-312016-07-312017-07-312018-12-31
Revenue02101814
Cost of Revenue
Gross Profit
R&D002238
SG&A411616811
Tax000010
Net Income-5-11-7-87-21
Cash Flow ($MM)2013-07-312014-07-312015-07-312016-01-312016-07-312017-07-312018-12-31
Cash Operating-1-1-4-16-1
Cash Investing00-00
Cash Financing1142-017